EXCLUSIVE: Cancer Firm Plus Therapeutics Licenses Diagnostic Assay To Detect Central Nervous System Cancers
EXCLUSIVE: Cancer Firm Plus Therapeutics Licenses Diagnostic Assay To Detect Central Nervous System Cancers
Before January 1, 2024, Plus Therapeutics will have the option for exclusivity for the field of radiotherapy in exchange for a $1.0 million payment, to be exercised at Plus Therapeutics' discretion.Plus Therapeutics Inc (NASDAQ:PSTV) has expanded its supply agreement with Biocept Inc (NASDAQ:BIOC) by acquiring an option to exclusively license Biocept's CNSide, a cerebrospinal fluid (CSF)-based tumor cell capture and enumeration platform, for patients receiving CNS radiotherapy.
Plus Treeutics Inc.(納斯達克股票代碼：PSTV)擴大了與Biocept公司(納斯達克：BIOC)通過獲得Biocept的獨家許可選擇權CNSide，一個基於腦脊液(CSF)的腫瘤細胞捕獲和計數平臺，用於接受中樞神經系統放射治療的患者。
Under the terms of the agreement, CNSide developer Biocept has granted Plus Therapeutics a non-exclusive license to its CNSide cell enumeration assay for Plus' investigational therapy for leptomeningeal metastases (LM), rhenium (186Re) obisbemeda and an option for an exclusive license to the assay.
根據協定條款，CNSide開發商Biocept已向Plus Treateutics授予其CNSidePlus用於軟腦膜轉移瘤(LM)、Re(186Re)obisbemeda的研究治療的細胞計數試驗，以及獲得該試驗獨家許可的選項。
In exchange, Plus Therapeutics will provide $150,000 in stock to Biocept.
作為交換，Plus Treateutics將向Biocept提供15萬美元的股票。
Before January 1, 2024, Plus Therapeutics will have the option for exclusivity for the field of radiotherapy in exchange for a $1.0 million payment, to be exercised at Plus Therapeutics' discretion.
在2024年1月1日之前，Plus Treateutics將有權選擇獨家經營放射治療領域，以換取100萬美元的付款，這筆付款將由Plus Treateutics酌情行使。
"Thus far, in our ReSPECT-LM trial, we have had a very positive experience with the CNSide assay and think it has significant potential," said Marc Hedrick, President & CEO of Plus Therapeutics.
到目前為止，在我們的尊重-LM試驗中，我們獲得了非常積極的經驗CNSidePlus Treeutics首席執行官兼首席執行官Marc Hedrick表示：“我們正在進行化驗，並認為它具有巨大的潛力。
CNSide is an assay based on a proprietary quantitative tumor cell capture method paired with digital imaging and molecular markers used to detect, characterize, and quantify tumor cells in CSF of patients with a variety of solid organ carcinomas and suspected LM, particularly breast and lung cancer and melanoma which are leading causes of LM.
CNSide是一種基於專有的定量腫瘤細胞捕獲方法的分析方法，結合數位成像和分子標記用於檢測、表徵和量化各種實體器官癌和疑似LM患者腦脊液中的腫瘤細胞，特別是乳腺癌、肺癌和黑色素瘤，這是導致LM的主要原因。
In March 2023, Biocept initiated enrollment in the FORESEE trial with CNSide to evaluate the performance of CNSide in monitoring LM's response to treatment and to assess the impact of CNSide on treatment decisions.
2023年3月，Biocept開始在Preee試驗中登記，CNSide評估……的表現CNSide在監測LM對治療的反應和評估CNSide關於治療決定的。
The feasibility phase of the study is expected to be completed in 1H of 2024, followed by a validation phase estimated to include between 40 and 100 subjects.
該研究的可行性階段預計將於2024年上半年完成，隨後的驗證階段估計包括40至100名受試者。
Price Action: PSTV shares closed at $2.97 on Thursday.
價格行動：PSTV股價週四收於2.97美元。
